Development and Validation of a Clinical Risk Score to Predict Immune-mediated Liver Injury Caused by Sintilimab: Assessed for Causality Using Updated RUCAM
Open Access
- 7 July 2023
- journal article
- research article
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 000 (000) , 000
Abstract
Immune-mediated liver injury is a fatal side effect of sintilimab. This study aimed to shed light on the associated risk factors and characteristics of this adverse event.Keywords
This publication has 24 references indexed in Scilit:
- RUCAM in Drug and Herb Induced Liver Injury: The UpdateInternational Journal of Molecular Sciences, 2015
- Nitrofurantoin-Induced Hepatotoxicity: A Rare Yet Serious ComplicationSouthern Medical Journal, 2014
- Comparison of the relationships of alcoholic and nonalcoholic fatty liver with hypertension, diabetes mellitus, and dyslipidemiaJournal of Clinical Biochemistry and Nutrition, 2013
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Update on Immunologic Therapy With Anti–CTLA-4 Antibodies in Melanoma: Identification of Clinical and Biological Response Patterns, Immune-Related Adverse Events, and Their ManagementSeminars in Oncology, 2010
- Chronically inflamed livers up-regulate expression of inhibitory B7 family members #Hepatology, 2009
- Ipilimumab: controversies in its development, utility and autoimmune adverse eventsCancer Immunology, Immunotherapy, 2009
- Enhancing SIV-specific immunity in vivo by PD-1 blockadeNature, 2008
- Automated variable selection methods for logistic regression produced unstable models for predicting acute myocardial infarction mortalityJournal of Clinical Epidemiology, 2004
- Evaluation of Clinical and Immunogenetic Risk Factors for the Development of Hepatotoxicity during Antituberculosis TreatmentAmerican Journal of Respiratory and Critical Care Medicine, 2002